The overexpression of EZH2 is related to worse survival in NK/T-cell lymphoma, prostate cancer, breast cancer, cutaneous melanoma, gastric cancer, endometrial cancer, and esophageal squamous cell carcinoma (Bachmann et al., 2006; Wei et al., 2008; Cai et al., 2010; Liu et al., 2019). Here, EZH2 is linked to breast carcinoma.